

Zoumpourlis Vassilis

Director of Research, Head of the research team of Biomedical Applications Unit,
Institute of Biology, Medical Chemistry and Biotechnology

Phone: +30-210-7273730 (Office), 7273731 (Lab)

Fax: +30 210 7273677

E-mail: vzub@eie.gr

Website: <http://www.eie.gr/nhrf/institutes/ibrb/serviceunits/bau-en.html>

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Univ. J E Purkyne, Brno, Czech Rep. (1981-1986)	Diploma	5	Mol. Biology and
Univ. J E Purkyne, Brno, Czech Rep. (1986-1987)	M.Sc.	1	Mol. Genetics
Nat Hellenic Research Foundation (1989-1994)	PhD	4	Mol. Biology of HIV-1
Nat Hellenic Research Foundation (1994-1998)	Post-Doc/	5	Mol. Biology of cancer

Positions and Employment

1989-1994 PhD, IBRB, NHRF Post-Doc

1994-1998 Post-Doc

1998-2003 Functional Scientist, Grade B, IBMCB, NHRF

2003-2006 Functional Scientist, Grade A, IBMCB, NHRF

2006-2013 Research Associate Professor, IBMCB, NHRF

20013- Research Professor, Researcher A, IBMCB, NHRF

2002- Head of the research team of Biomedical Applications Unit, IBMCB, NHRF.

RESEARCH ACTIVITIES ABROAD

1992	Visitor researcher, Molecular Oncology Group, Department of Clinical Dental Sciences, The University of Liverpool, UK
1993	Visitor researcher, Molecular Oncology Group, Department of Clinical Dental Sciences, The University of Liverpool, UK
1995	Visitor researcher, Marie Curie Institute, Paris, France
1998	Visitor researcher, Department of Molecular Cell Biology, Sylvius Laboratory, Leiden, Netherlands
2002	Visitor researcher, Department of Molecular Biology, Amsterdam, Netherlands
2004	Visitor researcher, Department of Molecular Oncology, Mazaryk Institute, Brno, Czech R
2005	Visitor researcher, Department of Molecular Oncology, Mazaryk Institute, Brno,

	Czech R
2007	Visitor researcher, Paterson Institute, Department of Cancer Research, Manchester, UK
2007	Visitor researcher, Roy Castle Lung Cancer Institute, The University of Liverpool, Department of Clinical and Molecular Cancer Medicine, UK
2008	Visitor researcher, UCSF Comprehensive Cancer Center, University of California, San Francisco, USA

Research Records

- **74** publications in international peer review scientific journals.
- **19** publications in refereed proceedings of international conferences and book chapters
- **7** Submitted publications in international peer review scientific journals

Full publications list: <http://www.ncbi.nlm.nih.gov/pubmed?term=zoumpourlis%20v>

- **Total Impact Factor, F > 350**

- **average value of Impact Factor per publication 4.6**

- **3330 citations** (13/ 11/ 2016, *My google scholar citation*)

- **h-Index = 28** (13/11/ 2016)

- **115** publications in proceedings of Greek and international conferences.

- **25** publications in Greek

Experience in Education

Supervision of 10 diplomas, 8 Master thesis, 17 PhD thesis and 8 Post-Doc Researchers.

2004-2016: Lecturer at Msc classes, Medical School, University of Athens Pharmaceutical Department, University of Patras, Molecular Biology Department, Democretian, University of Thrace, Faculty of Biology, Kapodistrian University of Athens. Topic: Molecular mechanisms of cancer in mouse and human models, stem cell Biology.

Research interests

The interests of Dr Vasilis Zoumpourlis' group cover the field of the molecular biology of cancer, mainly the study of genes with a crucial role in the molecular mechanisms of multistage carcinogenesis (initiation, promotion, progression) and metastasis. Dr Vasilis Zoumpourlis' group has recently extended its activities towards the intriguing research of stem cells and their applications in cancer therapeutics. The current challenge of Dr Vasilis Zoumpourlis' group is to develop new generation translational products for cytotherapy-based cancer management and testing of drugs. To this end, it has recently transferred its long-term experience and know-how in molecular biology of cancer in the emerging field of stem-cell biology, in order (a) to design stem cell-based vehicles for effective and specific tumour targeting and (b) to develop improved *in vitro*

preclinical assays for quick and reliable assessing of toxicology and safety profiles of drugs.

List of publications

Peer-reviewed Publications

1. Christodoulou I, Kritikos A, Koliakos G and Zoumpourlis V. Exploring the use of mesenchymal stem cell population in cancer cytotherapy. ***Stem Cells Int. Submitted 2016***
2. Christodoulou I, Kritikos A, Koliakos G and Zoumpourlis V. Human MSC Derived From Fetal Umbilical Cord (Wharton's Jelly) Serve As An Accurate Model For Acute Drug Toxicity Screening. ***Plos One Submitted 2016.***
3. Christodoulou I., Goulielmaki M, Koliakos G. and Zoumpourlis V. Exploring the use of mesenchymal stem cell population in cancer cytotherapy – advances and challenges. ***Stem Cells Int. Submitted 2016***
4. Sotiris Galtsidis, Stella Logotheti, Athanasia Pavlopoulou, Christos P. Zampetidis, Georgia Papachristopoulou, Andreas Scorilas, Borek Vojtesek, Vassilis Gorgoulis and Vassilis Zoumpourlis. Sequence-independent conservation of MIR3158's participation and function in a p73-regulated network mediating cell migration. ***Cancer letters Submitted 2016***
5. Antonis Kyriakopoulos and Vassilis Zoumpourlis. Inflammatory Propagation and Links to Cancer by NSAIDs. Can treatment be optimized? ***Cancer Research Submitted 2016***
6. Constantinos Potamitis, Maria Goulielmaki, Eleni Taki, Ioannis Christodoulou, Vassilis Zoumpourlis, Alexander Pintzas, Panagiotis Zoumpoulakis, Maria Zervou. Discovering selective inhibitors of the oncoprotein BRAFV600E through virtual screening methods and in vitro assays. ***In Preparation 2016***
7. Lucia Sommerova, Eva Ondrouskova, Sotiris Galtsidis, Rudolf Nenutil, Vassilis Zoumpourlis, Borivoj Vojtesek and Roman Hrstka. AGR2 is directly involved in the regulation of the epithelial phenotype during EMT. ***Moleccular Cell Submitted 2016***
8. Rizos E and Zoumpourlis V. miRNAs in Schizophrenia and cancer. ***Mol Med Rep. 2016 Oct 14. doi: 10.3892/mmr.2016.5853. [Epub ahead of print]***

9. Voulgari Efstathia, Bakandritsos Aristides, Winnefeld Frank, Galtsidis Sotiris, Zoumpourlis Vassilis and Avgoustakis Konstantinos. Magnetic nano-assemblies with PEG graft copolymers for the targeted delivery of cisplatin to tumors. ***J of controled release pii: S0168-3659(16)31044-6. doi: 10.1016/j.jconrel.2016.10.021. [Epub ahead of print]***

10. Katerina Georgadaki, Nikos Khoury, Demetrios Spandidos and Vasilis Zoumpourlis. The Molecular basis of Fertilization. ***Int J Mol Med. 2016 Oct;38(4):979-86. doi: 10.3892/ijmm.2016.2723***

11. Dinda B, Kyriakopoulos AM, Dinda S, Zoumpourlis V, Thomaidis NS, Velegraki A, Markopoulos C, Dinda M. Cornus mas L. (cornelian cherry), an important European and Asian traditional food and medicine: Ethnomedicine, phytochemistry and pharmacology for its commercial utilization in drug industry. ***J Ethnopharmacol. 2016 Oct 2. pii: S0378-8741(16)30929-1. doi: 10.1016/j.jep.2016.09.042. [Epub ahead of print]***

12. Nekulova M., Holcakova J., Gu X., Hrabal, V Galtsidis S., Orzoł P., Liu Y., Zoumpourlis V., Nylander K., Coates P and Vojtěšek B. ΔNp63a expression induces loss of cell adhesion in triple-negative breast cancer cells. ***BMC Cancer. 2016 Oct 10;16(1):782.***

13. Logotheti S., Houry N., Skourti H., Budunova I., Kyriakopoulos A., and V Zoumpourlis. Loss of antiproliferative response of cancer cells associated with impaired glucocorticoid receptor is bypassed by N-bromotaurine. ***Transl Res. 2016 Jul;173:58-73.e2. doi: 10.1016/j.trsl.2016.03.009. Epub 2016 Mar 21.***

14. Skourti E, Logotheti S, Kontos Ch, Pavlopoulou A, Dimoragka P, Trougakos I, Gorgoulis V, Scorilas A, Ioannis Michalopoulos I and Zoumpourlis V. Altered expression of miR-200 family members, miR-205 and their co-regulated mRNA targets during mouse skin carcinogenesis. ***Mol Carcinog. 2016 Aug;55(8):1229-42. doi: 10.1002/mc.22365. Epub 2015 Aug 2***

15. Georgia Saxami, Athanasios Karapetsas, Eleftheria Lamprianidou, Ioannis Kotsianidis, Aikaterini Chlichlia, Chrysoula Tassou, Vassilis Zoumpourlis, Alex Galanis. Two potential probiotic lactobacillus strains isolated from olive

microbiota exhibit adhesion and anti-proliferative effects in cancer cell lines.
***Journal of Functional Foods* 24 (2016) 461–471**

16. Rudrapaul P, Kyriakopoulos A, Chandra De U, Zoumpourlis V and Dinda B. New flavonoids from the fruits of *Cornus mas*, Cornaceae. ***Phytochemistry letters* 11, 292-295, 2015**

17. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, Tsoporis J, Kastania A, Filippopoulou A, Xiros N, Margaritis D, Parker T, Papageorgiou Ch, Vassilios Zoumpourlis. Let-7, Mir-98 and Mir-181 as Biomarkers for Cancer and Schizophrenia. ***PLOS ONE* | DOI:10.1371/journal.pone.0123522 April 9, 2015**

18. Georgios Pampalakis, Osahon Obasuyi, Olga Papadodima, Aristotelis Chatziioannou, Vassileios Zoumpourlis, Georgia Sotiropoulou. Kallikrein-related peptidase 5 is a novel suppressor of breast cancer that may exert its effects by repressing the mevalonate pathway. ***Oncotarget* 5(9):2390-403, 2014**

19. Georgia Velimezi, Michalis Lontos, Konstantinos Vougas, Theodoros Roumeliotis, Maria Sideridou, Ayguel Dereli-Oz, Maciej Kocylowski, Ioannis S Pateras, Kostas Evangelou, Athanassios Kotsinas, Ines Orsollic, Sladana Bursac, Maja Cokaric-Brdovak, Vassilis Zoumpourlis, Dimitris Kletsas, George Papafotiou, Apostolos Klinakis, Sinisa Volarevic, Wei Gu, Jiri Bartek, Thanos D. Halazonetis, Vassilis Gorgoulis. Functional interplay between the DNA damage response kinase ATM and ARF tumour suppressor protein in human cancer. ***Nat Cell Biol.* 2013 Aug;15(8):967-77. doi: 10.1038/ncb2795. Epub 2013 Jul 14.**

20. Logotheti S, Pavlopoulou A, Galtsidis S, Vojtesek B. and Zoumpourlis V. Functional discrimination of TAp73 isoforms in oncogenesis based on differences in their C-terminal domain. ***Cancer Metastasis Rev* (2013) 32:511–534, DOI 10.1007/s10555-013-9424-x**

21. Christodoulou I, Kollis FN, Papaevangeliou D and V Zoumpourlis. Proliferation kinetics and phenotypic properties of hMSCs derived from fetal umbilical cord (Wharton's jelly) and adult adipose tissue during prolonged in vitro culture. ***Stem Cells International, Volume 2013, Article ID 246134, 12 pages. 2013***

- 22.**Georgakopoulou E.A., Tsimaratou K1, Evangelou K1., Pablo Jose Fernadez Marcos, Zoumpourlis V, Trougakos IP., Kletsas D, Bartek J., Serrano M., Gorgoulis VG. Specific lipofuscin staining by Sudan Black B as a novel approach to detect senescent cells in vitro, as well as in cryo-preserved and archival tissues. ***Aging J Aging (Albany NY) Jan 5;5(1):37-50, 2013***
- 23.**Hio Chung Kang, Yuichi Wakabayashi, Kuang-Yu Jen, Jian-Hua Mao, Vassilis Zoumpourlis, Reyno De Rosario, and Allan Balmain. Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14PtchFVB mice. ***International J of Dermatology, Dec 6. doi: 10.1038/jid.2012.419, 2012***
- 24.**Rizos E, Siafakas N, Koumarianou A, Katsantoni E, Filippopoulou A, Ntounas P, Touloumis Ch, Kastania A, Zoumpourlis V. miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects. ***Oncol Rep. 2012 Dec;28(6):2200-4. doi: 10.3892/or.2012.2052. Epub 2012 Sep 21.***
- 25.**Stella Igotheti, Dimitra Papaevangelou, Ioannis Christodoulou, Katerina Pырillou, John Michalopoulos, Vassilis G. Gorgoulis, Spiros Vlachopoulos and Vassilis Zoumpourlis. Involvement of Estrogen Receptor alpha (ERα) in Mouse Skin Carcinogenesis ***PLoS One.;7(8):e41957. Epub 2012 Aug 3, 2012***
- 26.**Ioannis Aivaliotis, Antonia Daleziou, Ioannis Pateras, Vassilis Zoumpourlis. "How do cytokines trigger genomic instability?" ***J Biomed Biotechnol. :536761. Epub 2012 Jun 17, 2012***
- 27.**Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V, Spandidos DA. Expression profile of Rho kinases in urinary bladder cancer. ***J. BUON 16(3):511-21, 2011***
- 28.**Alexandros Daskalos, Soultana Markopoulou, George Xenarianos, John R Cosney, Stella Igotheti, Vassilis Zoumpourlis. John K. Field, and Triantafyllos Liloglou. Global DNA hypomethylation-induced DNP73 transcriptional activation in non-small cell lung cancer. ***Cancer Letters 300:79-86, 2011***
- 29.**Igotheti S, Michalopoulos I, Sideridou M, Daskalos A, Kossida S, Spandidos DA, Field JK, Vojtesek B, Liloglou T, Gorgoulis V, Zoumpourlis V. Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. ***FEBS J 277: 3014-3027, 2010***

- 30.**Rizos EN, Michalopoulou PG, Siafakas N, Stefanis N, Douzenis A, Rontos I, Laskos E, Kastania A, Zoumpourlis V, Lykouras L. Association of Serum Brain-Derived Neurotrophic Factor and Duration of Untreated Psychosis in First-Episode Patients with Schizophrenia. ***Neuropsychobiology* 62: 87-90, 2010**
- 31.**Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. ***Toxicol Lett.* 193: 131-137, 2010**
- 32.**Vassilis G. Gorgoulis, Michalis Liontos, Katerina Niforou, Georgia Velimezi Konstantinos Vougas, Konstantinos Evangelou, Radek Vrta, Alexandros Damalas, Panayiotis Kontovazenitis, Athanassios Kotsinas, Vassilis Zoumpourlis, George Th. Tsangaris, Christos Kittas, Doron Ginsberg, Thanos D. Halazonetis and Jiri Bartek³ Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. ***Am J Pathol.* 175:376-91, 2009.**
- 33.**Woodcock S, Rooney C, Liontos M, Connolly Y, Zoumpourlis V, Whetton A, Gorgoulis V and A Malliri. Src-induced disassembly of adherens junctions requires localised phosphorylation and degradation of Tiam-1. ***Molecular Cell* 33, 1-15, 2009.**
- 34.**Copland J, Sheffield-Moore M, Koldzic Zivanovic C, Lamprou G, Tzortzatou-Stathopoulou F, Zoumpourlis V, Urban R, and Vlahopoulos S Sex steroids and their receptors at the crossroads between differentiation and neoplasia: a perspective for therapeutic intervention. ***Bioessay* 31:629-41, 2009**
- 35.**Georgios Pampalakis, Evangelia Prosnikli, Theodora Agalioti, Antonia Vlahou, Vassilis Zoumpourlis and Georgia Sotiropoulou. A tumor protective role for human kallikrein 6 in breast cancer. ***Cancer Res* 69: 3779-87, 2009.**
- 36.**Frydrych I, Mlejnek P, Dolezel P, Zoumpourlis V, Krumpochova P. The broad-spectrum caspase inhibitor Boc-Asp-CMK induces cell death in human leukaemia cells. ***Toxicol in Vitro* 22: 1356-60, 2008**
- 37.**Spiros A. Vlahopoulos, Stella Logotheti, Dimitris Mikas, Athina Giarika, Vassilis Gorgoulis and Vassilis Zoumpourlis. The role of ATF-2 in oncogenesis. ***Bioessay* 30: 314-327, 2008.**

- 38.** Bakas P, Liapis A, Vlahopoulos S, Giner M, Logotheti S, Creatsas G, Meligova AK, Alexis MN, Zoumpourlis V. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. ***Fert. Ster. 1: 1-8, 2008***
- 39.** Lontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, Lygerou Z, Taraviras S, Kittas C, Bartkova J, Papavassiliou AG, Bartek J, Halazonetis TD, Gorgoulis VG. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. ***Cancer Research 67: 10899 -10909, 2007***
- 40.** Bartkova J, Rezaei N, Lontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. ***Nature 444: 633-637, 2006***
- 41.** Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis V and Schwartz RJ. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. ***JBC 280: 7786-9, 2005***
- 42.** Papoutsis Z, Kassi E, Papaevangelidou D, Pratsinis H, Zoumpourlis V, Halabalaki M, Mitakou S, Kalofoutis A and P moutsatsou. Plant 2-Arylobenzofurans demonstrate a selective estrogen receptor modulator profile. ***Steroids 69: 727-734, 2004***
- 43.** Papassava P, Gorgoulis V, Papaevangelidou D, Vlahopoulos S, van Dam H, and Zoumpourlis V. Overexpression of Activated Transcription Factor 2 is required for tumor growth and progression in mouse skin tumors. ***Cancer Res 64: 8573-8584, 2004.***
- 44.** Vlachopoulos S and V Zoumpourlis. "JNK": a key modulator of intracellular signaling. ***Biochemistry (Moscow) 69: 844-854, 2004***
- 45.** Zoumpourlis V, Solakidi S., Papatoma A. and Papaevangelidou D. Genetic alterations in signal transduction pathways implicated in tumour progression

during multistage mouse skin carcinogenesis. ***Carcinogenesis* 24: 1159-1165, 2003.**

- 46.**Gorgoulis V, Zacharatos P, Mariatos G, Kletsas D, Zoumpourlis V, Kittas Ch, Ryan K and Papavassiliou A.. p53 activates ICAM-1 (CD54) expression in an NF- κ B-independent manner. ***EMBO J* 22: 1567-1578, 2003**
- 47.**Gazouli M, Kokotas S, Zoumpourlis V, Zacharatos P, Mariatos G, Kletsas D, Kittas Ch and Gorgoulis V. The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein. ***Anticancer Research* 22: 4237-4242, 2002.**
- 48.**Katsanakis KD, Gorgoulis V, Papavassiliou A and Zoumpourlis V. The progression in the mouse skin carcinogenesis model is dependent on ERK1/2 signaling. ***Molecular Med* 8: 624-637, 2002**
- 49.**Psichari E, Balmain A, Plows D, Zoumpourlis V and Pintzas A. High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by Rho signaling. ***J Biol Chem.* 277, 29490-29495, 2002.**
- 50.**Katsanakis K, Owen C, Zoumpourlis V. JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their *in vivo* biological role. ***Anticancer Research* 22, 755-760, 2002.**
- 51.**Plows D, Briassouli P, Owen C, Zoumpourlis V, Garrett M and A Pintzas. Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. ***Biochem J* 362, 305-315, 2002**
- 52.**Papathoma A, Zoumpourlis V, Balmain A and A Pintzas. Role of Matrix Metalloproteinase-9 in Progression of Mouse Skin Carcinogenesis. ***Molecular Carcinogenesis* 31, 74-82, 2001.**
- 53.**Kotsinas A, Gorgoulis VG, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos Zoumpourlis V, Kyroudi A, Field JK, Asimakopoulos PJ and Kittas Ch. Additional characterizaation of a hexanucleotide polymorphic site in the first

intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. ***Cancer Genetics and Cytogenetics* 126, 147-154, 2001**

54.Gorgoulis VG, Zacharatos P, Mariatos G, Liloglou T, Kokotas S, Kastrinakis N, Kotsinas A, Athanasiou A, Foukas P, Vogiatzi T, Zoumpourlis V, Kletsas D, Ikonomopoulos J, Asimakopoulos PJ, Rossidakis G, Kittas Ch and Field JK. Deregulated expression of c-mos in non-small cell lung carcinomas: Relationship with p53 status, genomic instability and tumor kinetics. ***Cancer Research* 61, 538-549, 2001**

55.Zoumpourlis Vassilis, Papassava Paraskevi, Linardopoulos Spyros, Gillespie David, Balmain Allan and Alexandros Pintzas. High levels of phosphorylated c-jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. ***Oncogene* 19, 4011-4021, 2000.**

56.Gorgoulis VG, Zacharatos PV, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, Foukas P, Rassidakis G, Garinis G, Ioannides T, Zoumpourlis V, Michail P O, Manolis EN, Field JK and Kittas Ch. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and genomic instability in Non-Small Cell Lung Carcinomas (NSCLCs). ***Molecular Medicine* 6, 208-237, 2000**

57.Gorgoulis V, Zacharatos P, Manolis E, Ikonomopoulos A, Damalas A, Rassidakis G, Zoumpourlis V, Kotsinas A, Rassidakis AN, Halazonetis T and Kittas C. Effects of p53 mutants derived from lung carcinomas bind the p53 - responsive element (p53 RE) of the MDM-2 gene. Relationship with MDM-2 expression. ***British Journal of Cancer* 77, 374-384, 1998**

58. Christeli E, Zoumpourlis V, Kiaris H, Ergazaki M, Vassilaros S and Spandidos DA. TGF- β 1 overexpression in breast cancer. Correlation with clinicopathological data. ***Oncology Reports* 3, 115-118, 1996**

59.Gorgoulis V, Zoumpourlis V, Rassidakis GZ, Rassidakis AN, Spandidos DA and Kittas Ch. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. ***Journal Pathology* 180, 129-137, 1996.**

- 60.** Zoumpourlis V and Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by retinoic acid in human epithelial and fibroblast tumor cell lines. *Journal of Biological Markers* **11**, 153-158, 1996.
- 61.** Zoumpourlis V, Zachos G, Halazonetis TD and Spandidos DA. Binding of wild-type and mutant forms of p53 protein in a specific DNA sequence of the first intron of the H-ras oncogene. *International Journal of Oncology* **7**, 1035-1041, 1995.
- 62.** Spandidos DA, Zoumpourlis V, Zachos G, Toas SH and Halazonetis TD. Specific recognition of a transcriptional element within the human H-ras proto-oncogene by the p53 tumor suppressor. *International Journal of Oncology* **7**, 1029-1034, 1995.
- 63.** Zachos G, Zoumpourlis V, Sekeris CE and Spandidos DA. Binding of the glucocorticoid and estrogen receptors to the human c-H-ras oncogene sequences. *International Journal of Oncology* **6**, 595-600, 1995.
- 64.** Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K, Whittaker J, Howard P, Beirne JC, Gosney JR, Woolgar J, Vaughan ED, Spandidos DA and Jones AS. Head and neck cancer allelotype indicates as ordered allele loss consistent with a two hit model of carcinogenesis. *British Journal of Cancer* **72**, 1180-1188, 1995.
- 65.** Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA and Kittas C. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. P53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen (PCNA) labelling index. *Virchows Archives* **426**, 339-344, 1995.
- 66.** Spandidos DA, Zoumpourlis V, Gorgoulis V and Gourtsoyiannis NC. P53 expression in human small intestinal tumours. *Oncology Reports* **1**, 885-889, 1994.
- 67.** Field JK, Zoumpourlis V, Spandidos DA and Jones AS. P53 expression and mutations in squamous cell carcinoma of the head and neck: Expression correlates with the patients use of tobacco and alcohol. *Cancer Detection and Prevention* **18**, 197-208, 1994.

- 68.**Zoumpourlis V, Papadakis E, Delakas D, Cranidis A, Segas J, Papadakis H and Spandidos DA. Human lung, bladder and head and neck carcinoma tumors as compared to their normal tissue have elevated AP-1 activity and recognize sequence elements of the HIV-1 LTR. *Oncology Reports 1, 403-409, 1994*
- 69.**Zoumpourlis V, Ergazaki M and Spandidos DA. AP-1 recognizes sequence elements on HIV-1 LTR in human epithelial tumour cell lines. *Oncology Reports 1, 397-401, 1994.*
- 70.**Field JK, Tsiriyotis C, Zoumpourlis V, Howard P and Jones AS. Allele loss on chromosome 3 in squamous cell carcinoma of the head and neck correlates with poor clinical prognostic indicators. *International Journal of Oncology 4, 543-549, 1994.*
- 71.**Zoumpourlis V and Spandidos DA. Mitomycin C stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts. *Biochemical Pharmacology 46, 178-181, 1993.*
- 72.**Spandidos DA, Eliopoulos A and Zoumpourlis V. Regulation of oncogene and AIDS virus expression by cis-platin compounds. *Journal of Chemotherapy 5, 778-779, 1993.*
- 73.**Zoumpourlis V, Kerr DJ and Spandidos DA. Differential interaction of cis-platin with HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. *Anti-Cancer Drugs 4, 77-83, 1993.*
- 74.**Zoumpourlis V and Spandidos DA. Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts. *Anti-cancer Drugs 3, 163-167, 1992.*
- 75.**Zoumpourlis V, Eliopoulos A and Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumour necrosis factor. *Anticancer Research 12, 2065-2068, 1992.*
- 76.**Zoumpourlis V, Kerr DJ and Spandidos DA. Carboplatin as opposed to cis-platin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. *Biochemical Pharmacology 43, 650-654, 1992.*

- 77.** Zoumpourlis V, Kerr DJ and Spandidos DA. Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. **Cancer Letters 56, 181-185, 1991.**
- 78.** Spandidos DA, Zoumpourlis V, and Lang JK. Cis-platin responsive sequences in the human c-myc promoter. **Anticancer Research 11, 1339-1342, 1991.**
- 79.** Spandidos DA, Zoumpourlis V, Kotsinas A, Tsiriyotis C and Sekeris CE. Response of human immunodeficiency virus long terminal repeat to growth factors and hormones. **Anticancer Research 10, 1241-1246, 1990.**
- 80.** Zoumpourlis V, Patsilidakos P, Kotsinas A, Maurer HR, Lenas P and Spandidos DA. Cis-platin stimulates the expression from the human immunodeficiency virus long-terminal repeat sequences in human fibroblasts. **Anti-Cancer Drugs 1, 55-58, 1990**
- 81.** Spandidos DA, Zoumpourlis V, Kotsinas A, Maurer HR and Patsilidakos P. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by cis-platin. **Genetic Analysis Techniques and Applications 7, 138-141, 1990.**

Publications in refereed proceedings of international conferences and book chapters

- 82.** Spandidos DA, Chatzipanagiotou M and Zoumpourlis V. Prognostic significance of oncogenes and onco-suppressor genes in lung cancer. In: Proceedings of Seminar on Lung Cancer. **European School of Oncology. Pp 26-29, 1994.**
- 83.** Spandidos DA, Chatzipanagiotou M and Zoumpourlis V. Oncogene and onco-suppressor gene lesions in lung cancer. In : **Proceedings of the International Congress for Lung Cancer. G. Antypas (Ed.) Monduzzi Editore S.p.A. Bologna, Italy, pp 41-45, 1994.**
- 84.** Pintzas A, Zoumpourlis V and D Plows. Regulation of components of AP-1 transcription factor by early and late Ras signals. "Molecular mechanisms of signal transduction", **JL Bos (Ed.), IOS Press, 57-61, 2000**

85. Zoumpourlis V, Papassava P, Pintzas A, Moutsatsou P and Katsanakis K. AP-1 transcription factors and steroid hormone receptors in multistage mouse skin carcinogenesis. *Epitheorese klinikes Farmakologias kai Farmakokinetikes*, **15**, 123-128, 2001.

86. Zoumpourlis V, Pintzas A, Papassava P, Solakidi S and Papaevangelliou. Biological and chemical approach of the inhibition of signaling cascade in mouse skin carcinogenesis. *Review of clinical Pharmacology and genetics, International Edition 16 (1)*, pp111, 2002

87. E Psichari, A Balmain, D Plows, V Zoumpourlis, A Pintzas. MECHANISMS OF SIGNAL TRANSDUCTION-High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. *Journal of Biological Chemistry 277 (33)*, 29490-29495, 2002

88. Vlahopoulos S and V Zoumpourlis. Structure of DNA and its relationship to cancer. *Chapter 1 pp 1-26, Genome and Proteome in Oncology, Nova Science, 2005*

89. Sotiropoulou G, Pampalakis G, Prosnikli E, Zoumpourlis V. Human kallikrein 6 suppresses the malignant phenotype of MDA-MB-231 human metastatic breast cancer cells. *AACR Meeting Abstracts, Volume 2006 (1)*, page 999, 2006

90. Volanis D, Zaravinos A, Kadiyska T, Zoumpourlis V, Delakas D, Spandidos DA. Expression analysis of the Rho kinases in urinary bladder cancer. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE*, S55-S55, 2010

91. Skourti E, Kontos, C, Scorilas A, and Zoumpourlis V. miR-200 family miRNAs and miR-3069 expression is significantly differentiated between early and late mouse skin carcinogenesis stages. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE*, S79-S79, 2013

92. E Rizos, N Siafakas, V Zoumpourlis. MicroRNAs as biomarkers for schizophrenia cancer and other CNS disorders-The role of mir-183 as a possible molecular protective biomarker for cancer in schizophrenic subjects. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 32*, S79-S79, 2013

93. S Galtsidis, S Logotheti, A Pavlopoulou, B Vojtesek, V Zoumpourlis. The miRNA-mediated effect of TAp73 isoforms on metastasis. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34*, S75-S75, 2014.

94. E Rizos, N Siafakas, E Katsantoni, V Zoumpourlis. Schizophrenia and cancer: the key role of microRNAs as biomarkers in cancer, schizophrenia and other CNS disorders ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S62-S62, 2014.***

95. I Christodoulou, A Kritikos, V Zoumpourlis. The anti-proliferative effects of naive and genetically-modified hMSCs on human cancer cells. ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S75-S75, 2014.***

96. E Skourti, S Logotheti, CK Kontos, A Scorilas, IP Trougakos and V Zoumpourlis. MiR-200 family miRNAs and miR-205 exhibit a functional role in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S75-S75, 2014.***

97. V Zoumpourlis, E Skourti. The ideological frame of the determination of the genetic basis of cancer. ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S75-S75, 2014***

98. Stella Logotheti, Nikolas Khoury, Elena Skourti, Spiros A. Vlahopoulos, Vassilis Gorgoulis , Anthony M. Kyriakopoulos, Vassilis Zoumpourlis. Loss of antiproliferative response attributed to ablated glucocorticoid receptor function in mouse skin carcinogenesis is compensated by N-bromoamine taurine. ***FEBS J 282 Supplement 1 July 2015.***

99. Sotiris Galtsidis, Stella Logotheti, Borek Vojtesek, Vassilis Zoumpourlis. miR-3158: a TAp73-induced target which inhibits epithelial-mesenchymal transition through downregulation of vimentin. ***FEBS J 282 Supplement 1 July 2015.***

100. Christodoulou I, Kritikos A, Taki H, Zoumpourlis V. Naïve and genetically-modified hMSCs exhibit anti-proliferative effects on human cancer cells.. ***FEBS J 282 Supplement 1 July 2015.***

101. Evin Iscan, Umut Ekin, VassilisZoumpourlis , Khoury Nikos, Hani Alotaibi, Marta Nekulova, Borivoj Vojtesek, Stella Logotheti, Mehmet Oztürk. Mechanism of TAp73 beta-MDM2 Autoregulation. ***FEBS J Supplement 1 October 2016.***

102. Umut Ekin, Evin Iscan, Stella Logotheti Khoury Nikos, Hani Alotaibi, Sana Ferroudj, Marta Nekulova, Borivoj Vojtesek, Vassilis Zoumpourlis, Mehmet Oztürk.

TAp73-Beta Induces Tumor Inhibition in Hepatocellular Carcinoma. ***FEBS J Supplement 1 October 2016.***

103. Nicola Khoury, Georgios Pampalakis, Eleni Zingkou, Vassilis Zoumpourlis, Georgia Sotiropoulou. KLK6 protease promotes tumor incidence and growth in skin. The 46th Annual Meeting of the European Society for Dermatological Research, 7-10 September 2016, Munich, Germany

ii. Honors and Awards

1981: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)

1982: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)

1983: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)

1984: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)

1985: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)

1996: Hellenic Pneumonological Society, March 1996, 3rd prize

2000: Hellenic Society of General Pathology and Pathological Anatomy, 1st Galinos prize

2000: University of Athens, January, 3rd prize

2002: 4th Hellenic Conference of Cancer markers, 3rd prize

2007: 2nd Bioscience Conference, University of Patras, 1st prize

2007: 2nd Bioscience Conference, University of Patras, 2nd prize

2007: Fullbright award for academic period 2007-2008, for research in UCSF Comprehensive Cancer Center, University of California, San Francisco

2009: 3rd International Kallikrein Symposium, Minch Germany, 1st prize

iii. Reviewer for scientific journals

BBA–Molecular Cell Research, BMC, Cancer, Plos One, Carcinogenesis, Molecular Carcinogenesis, Oncogene, Cancer Letters, Cancer Biomarkers, Clinical Biochemistry, International Journal of Cancer, Tumor Biology, Advances Biomedicina, Oncotarget.

iv. Reviewer for grants

Ministry of Education, Greek Secretariat of Research and Technology, IPE Cyprus, The Czech Ministry of Education, The Austrian Federal Ministry of Education, The Italian Ministry of Education

v. invited speaker

>60

vi. Biomedical Applications Unit lab members (August 2016)

Ioannis Christodoulou, PhD, Post-Doctoral Research Fellow, Stem Cell Biology

Spiros Vlahopoulos, PhD, collaborator

Antonis Kyriakopoulos, PhD, collaborator

Gulielmaki Maria, PhD, Stem Cell Biology

Nikolas Houris PhD, Cancer Biology

Stella Baliou PhD, Cancer Biology

Maria Margariti, Diploma Student, Stem cell Biology

Elisavet Kritsotalaki MSc, Cancer Biology

Competitively funded Projects:

1. PENED (1999-2002) (*National Hellenic Research Foundation*). Research program on "Mechanism of interaction of selective steroid receptor modulators with AP-1", a competitive GSRT research network. Coordinator : V. Zoumpourlis (Budget 142 K€)

2. ENTER-01EP94: (2003-2007) : (*National Hellenic Research Foundation , Participant: Antisel SA*). "Role of MEF2 transcription factor in heart hypertrophy and cancer development". Coordinator: V. Zoumpourlis. (Budget 73.3 K€.)

3. Czech-Greek bilateral cooperation (2003-2005): (*National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech, Participant: Antisel SA*). "Role of the p53 oncosuppressor gene in androgen-independent prostate cancer". Contributor: Prof B Vojtesek, Coordinator: V. Zoumpourlis (Budget 24 K€)

4. French-Greek bilateral cooperation (2004–2006): (*National Hellenic Research Foundation, Institute Pasteur, Paris France, Participant: Antisel SA*). "Molecular mechanism for Androgen Receptor interaction with AP-1 in Prostate cancer". Contributor: Prof M Yaniv, Coordinator: V. Zoumpourlis (Budget 24 K€.)

5. USA - Greek bilateral cooperation (2005- 2008): (*National Hellenic Research Foundation*). «Molecular dissection of the mechanism of Rho kinase in susceptibility to cancer progression and metastasis». Contributor: Prof A Balmain, Coordinator: V. Zoumpourlis (Budget 60 K€.)

6. EU project: TOK (2007-): (*National Hellenic Research Foundation*). «Supramolecular chemistry and gene therapeutic potential of amine-amine-substituted cyclodextrin end-functionalized triazine dendrimers based on melamine" Contributor: V. Zoumpourlis, Coordinator: I Kostas (total Budget 332 K€)

7. Czech-Greek bilateral cooperation (2012-2014): (*National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech*). "The regulation of p73 gene and the role of TAp73 β isoform in lung cancer ". Contributor: Prof B Vojtesek , Coordinator: V. Zoumpourlis (Budget 15 K€)

8. ESPA (2012-2014) Action: *Support for New Business, Research & Technological Development (Bioellenica Biotechnology Company S.A, Thessaloniki, GR, National Hellenic Research Foundation)*. "The use of genetically modified adipose-derived MSC in

cancer cytotherapy. Coordinator: Prof. G Koliakos, Contributor: V. Zoumpourlis (total budget 200 K€; for National Hellenic Research Foundation 50 K€). This is a translational research program using the genetic modification of mesenchymal stem cells for cancer cytotherapy, through a robust collaboration with NHRF's spin-off Stem Cell Bank TAK-EIE, as well as with Biohellenika Biotechnology Company S.A.

9. Research in stem cells (2008-) (*National Hellenic Research Foundation, TAK EIE*). "Research of stem cells and their applications in cancer therapeutics". Coordinator: V. Zoumpourlis (total budget 200 K€).

10. KRYPTIS (2013-2015). Targeted therapeutic approaches against degenerative diseases with emphasis on cancer and aging. (*National Hellenic Research Foundation, Institute of Biology, Medical Chemistry and Biotechnology*) Contributor: V. Zoumpourlis (total budget 1500 K€ for Biomedical Application Unit budget 50 K€).

11. Greek – Turkey bilateral cooperation (2013-2015): (*National Hellenic Research Foundation, Bilkent University Department of Molecular Biology and Genetics*). "Role of p73 and its miRNA targets in chemosensitivity of liver cancer ". Contributor: Prof Mehmet Öztürk, Coordinator: V. Zoumpourlis (total budget 130 K€ for Biomedical Application Unit Budget 30 K€).

12. Czech-Greek cooperation (2014-2016): (National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech). "Comparative studies of wtp53 versus mutant p53 in scid mice. ". Contributor: Prof B Vojtesek , Coordinator: V. Zoumpourlis (Budget 12 K€)

13. IKY Fellowships of Excellence for Postgraduate Studies in Greece- Siemens Program. 2014-2016. Coordinator: Dr. V Zoumpourlis. Post-graduate research fellow: Dr. Stella Logotheti. Total budget: 40 K€. Lab budget: 40 K€.